Work

Building on the Promise of Cancer Vaccines for Solid Tumors

Year: 2019

Type: article

Abstract: A novel telomerase vaccine (INVAC-1) has been evaluated in a phase I clinical trial (n = 26). It induced CD8+ and CD4+ T-cell responses and reduced circulating regulatory T cells. The findings support further development, especially in combination with vaccine adjuvants, plus therapies to increase immune infiltrates into solid tumor metastases. See related article by Teixeira et al., p. 588

Source: Clinical Cancer Research

DOI: 10.1158/1078-0432.ccr-19-3206

Author: Craig L. Slingluff

Institutions: University of Virginia Cancer Center, University of Virginia

Language: English

Topic: Immunotherapy and Immune Responses

Subfield: Immunology

Field: Immunology and Microbiology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: green

Funders: National Cancer Institute, Congressionally Directed Medical Research Programs